Homocysteine in relation to cognitive performance in pathological and non-pathological conditions
Clinical Chemistry and Laboratory Medicine, ISSN: 1434-6621, Vol: 43, Issue: 10, Page: 1089-1095
2005
- 25Citations
- 57Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations25
- Citation Indexes25
- 25
- CrossRef15
- Captures57
- Readers57
- 57
Review Description
Elevated serum homocysteine has been associated with increased risk of Alzheimer's disease. Furthermore, elevated homocysteine levels are related to cognitive dysfunction in the elderly. The aim of the present study was to explore the disease specificity of the relation between serum total homocysteine levels and cognitive function. For this, we summarize data from several studies on homocysteine levels in both normal and pathological conditions performed in our laboratories and evaluate possible mechanisms of effects of elevated homocysteine levels in the central nervous system. Total homocysteine levels were measured in serum of: 1) healthy aging individuals; 2) patients with Alzheimer's and Parkinson's disease and patients with other cognitive disorders; and 3) patients with multiple sclerosis. Increased serum homocysteine concentration was related to worse cognitive performance over a 6-year period in the normal aging population (r= -0.36 to -0.14, p <0.01 for the Word learning tests; r=0.76, p<0.05 for the Stroop Colored Word test). Homocysteine was only increased in patients with Parkinson's disease on L-Dopa therapy (18.9 vs. 16.5 μmol/L in healthy controls), and not in dementia patients. Homocysteine was elevated in patients with progressive multiple sclerosis (15.0 μmol/L, n=39, compared to 12.0 μmol/L in 45 controls) and correlated to both cognitive and motorfunction (r= -0.33 and -0.33, p <0.05, respectively). The relationship between homocysteine and cognitive function in non-pathological and pathological situations indicates that changes in its levels may play a role in cognitive functioning in a broad spectrum of conditions. © 2005 by Walter de Gruyter. Berlin.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=27744555439&origin=inward; http://dx.doi.org/10.1515/cclm.2005.190; http://www.ncbi.nlm.nih.gov/pubmed/16197303; https://www.degruyter.com/view/j/cclm.2005.43.issue-10/cclm.2005.190/cclm.2005.190.xml; http://www.degruyter.com/view/j/cclm.2005.43.issue-10/cclm.2005.190/cclm.2005.190.xml; http://www.degruyter.com/view/j/cclm.2005.43.issue-10/cclm.2005.190/cclm.2005.190.pdf; https://www.degruyter.com/document/doi/10.1515/CCLM.2005.190/html
Walter de Gruyter GmbH
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know